Recent Press Releases

Crizotinib treatment effective against ROS1-positive lung cancer

Crizotinib treatment effective against ROS1-positive lung cancer Treatment led to significant tumor shrinkage in 72 percent of treated patients Treatment with the targeted therapy drug crizotinib...

Pfizer Completes Acquisition Of InnoPharma

Pfizer Completes Acquisition Of InnoPharma Thursday, September 25, 2014 - 8:00am EDT Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of the pharmaceutical development...

Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014

Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014 KEYTRUDA® monotherapy achieved...

GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma

GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma 29 September 2014 Issued: London, UK GSK today...

Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial

Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial Afinitor led to an unprecedented median overall survival of...

Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia(TM) as their first ALK inhibitor for ALK+ NSCLC

Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia(TM) as their first ALK inhibitor for ALK+ NSCLC Longest median progression-free survival (PFS) ever...

Roche's investigational combination of cobimetinib plus Zelboraf (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone

Roche's investigational combination of cobimetinib plus Zelboraf (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone • Cobimetinib plus Zelboraf...

Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Presentation of Phase 3 Results for a PD-1 Immune Checkpoint Inhibitor

Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Presentation of Phase 3 Results for a...

Boehringer Ingelheim's afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer

Boehringer Ingelheim's afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer Results from the LUX-Head & Neck 1 study show...

GENENTECH'S PERJETA REGIMEN EXTENDED THE LIVES OF PEOPLE WITH AN AGGRESSIVE TYPE OF METASTATIC BREAST CANCER BY 15.7 MONTHS COMPARED TO HERCEPTIN AND CHEMOTHERAPY

GENENTECH'S PERJETA REGIMEN EXTENDED THE LIVES OF PEOPLE WITH AN AGGRESSIVE TYPE OF METASTATIC BREAST CANCER BY 15.7 MONTHS COMPARED TO HERCEPTIN AND CHEMOTHERAPY Final data from Phase III CLEOPATRA...

AMAG Pharmaceuticals to Acquire Lumara Health Maternal Health Business

AMAG Pharmaceuticals to Acquire Lumara Health Maternal Health Business Accelerates transformation of AMAG to a Profitable, Multi-Product Specialty Pharmaceutical Company Adds FDA-Approved Therapy...

Kamada Announces Second Extension of Strategic Agreement with Baxter

Kamada Announces Second Extension of Strategic Agreement with Baxter NESS ZIONA, Israel, Sep 29, 2014 (BUSINESS WIRE) -- Kamada Ltd. KMDA, +0.45% (tase:KMDA), a plasma-derived protein therapeutics...

ZYTIGA(R) Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer

ZYTIGA(R) Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer...

Release from Jackson Square Partners

IRVINE, Calif., Sept. 27, 2014 -- /PRNewswire/ -- Michael Gallagher, Lead Independent Director Allergan, Inc. 2525 Dupont Drive Irvine, CA 92612 Mr. Gallagher: We have owned Allergan...

Roche purchases shares in tender offer for InterMune, Inc.

BASEL, Switzerland, Sept.

Health Care Equipment Equities under the Scanner - Medtronic, Abbott Laboratories, Stryker, Zeltiq Aesthetics, and EnteroMedics

Editor Note: For more information about this release, please scroll to bottom.

LONDON, September 26, 2014

Abbott Completes Acquisition of CFR Pharmaceuticals; Announces Results of Tender Offer for CFR Shares

Acquisition enhances Abbott's position in Latin America, more than doubling its branded generics pharmaceutical sales and presence in the fast-growing region

ABBOT

Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung

Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung Nintedanib*, when added to docetaxel, is the first lung cancer treatment to have...

FDA Approves Trulicity™ (dulaglutide), Lilly's Once-Weekly Therapy for Adults with Type 2 Diabetes

FDA Approves Trulicity™ (dulaglutide), Lilly's Once-Weekly Therapy for Adults with Type 2 Diabetes Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for...

Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director

Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director Overall Same Store Organic Growth (unadjusted for generics) Expected to Exceed 15% in...